3-ethylamino-3-phenyl-propionic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-ethylamino-3-phenyl-propionic acid
• 英文别名: 3-Aethylamino-3-phenyl-propionsaeure；3-(Ethylamino)-3-phenylpropanoic acid
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: CGSOFQSNVIOVLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  丙二酸 、 N-亚苄基乙胺 在 乙醇 作用下， 生成 3-ethylamino-3-phenyl-propionic acid
  参考文献：
  名称：

  Rodionow; Jaworskaja, Zhurnal Obshchei Khimii, 1955, vol. 25, p. 2147

  摘要：

  DOI：

文献信息

• [EN] NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY<br/>[FR] COMPOSITIONS DE NANOMATÉRIAU, SYNTHÈSE ET ASSEMBLAGE
  申请人：RHODE ISLAND HOSPITAL

  公开号：WO2016081522A1

  公开（公告）日：2016-05-26

  Compositions or an assembly of a series of biomimetic compounds include chemical structures that mimic or structurally resemble a nucleic acid base pair. Complexes of nanotubes and agents are useful to deliver agents into the cells or bodily tissues of individuals for therapeutic and diagnostic purposes. Exemplary compounds include those of Formula (I), (III), (V) or (VII), or of Formula (II), (IV), (VI) or (VIII).

  一系列仿生化合物的组成或装配包括模拟或在结构上类似于核酸碱基对的化学结构。纳米管和试剂的复合物可用于将试剂输送到个体的细胞或身体组织中，用于治疗和诊断目的。示例化合物包括Formula (I)、(III)、(V)或(VII)的化合物，或Formula (II)、(IV)、(VI)或(VIII)的化合物。
• Method for producing an optically activ beta-amino acid
  申请人：——

  公开号：US20040023344A1

  公开（公告）日：2004-02-05

  The Problem to Be Solved: To provide a producing method of an optically active &bgr;-amino acid useful as intermediate for the production of medicines, agricultural chemicals and physiologically active substances, by means of a catalytic and asymmetric synthesis method of high performance and a high enantiomeric excess, without requiring additional procedures such as introduction and removal of protecting group and so on. Means to Solve the Problems: A producing method of an optically active &bgr;-amino acids which comprises subjecting an enamine to an asymmetric hydrogenation.

  需要解决的问题：提供一种光学活性的β-氨基酸生产方法，作为制药、农药和生理活性物质的中间体，通过高性能和高对映体过量的催化不对称合成方法，而不需要额外的保护基引入和去除等程序。 解决问题的方法：一种生产光学活性β-氨基酸的方法，包括将恩酰胺进行不对称氢化。
• AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：Biediger Ronald J.

  公开号：US20130236434A1

  公开（公告）日：2013-09-12

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体的结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素选自α4β1、α5β1、α4β7、αvβ3和αLβ2群，然后将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；使用这种激动剂治疗表达整合素的细胞以增强结合的方法；以及包括将激动剂处理的细胞或激动剂化合物给哺乳动物的治疗方法。
• AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：TEXAS HEART INSTITUTE

  公开号：US20150368234A1

  公开（公告）日：2015-12-24

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素被选择自α4β1、α5β1、α4β7、αvβ3和αLβ2组成的群体中的一种，并将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；用这样的激动剂处理表达整合素的细胞以增强结合的方法；以及包括向哺乳动物施用经激动剂处理的细胞或激动剂化合物的治疗方法。
• Agonists that enhanced binding of integrin-expressing cells to integrin receptors
  申请人：TEXAS HEART INSTITUTE

  公开号：US10035784B2

  公开（公告）日：2018-07-31

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法，包括在体外用整合素的激动剂处理表达整合素的细胞，其中整合素选自由α4β1、α5β1、α4β7、αvβ3和αLβ2组成的组，并使处理过的细胞与整合素结合配体接触；具有通式Ⅰ的整合素激动剂化合物；用这种激动剂处理整合素表达细胞以增强结合的方法；以及治疗方法，包括给哺乳动物施用激动剂处理过的细胞或激动剂化合物。